Every 424B that Tiziana Life Sciences Ltd Com (TLSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TLSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLSA filings page.
Tiziana Life Sciences Ltd. is offering 8,800,000 common shares at $1.25 per share on a best efforts basis, with one warrant for each share. Each warrant allows the holder to buy one additional common share at $1.50 until July 16, 2026. The offering would generate gross proceeds of $8,800,000, and the company plans to use the funds, together with existing cash, primarily to complete Phase 2 clinical trials in non-active SPMS and MSA and to support broader development of its lead asset, foralumab.
Common shares outstanding are expected to be 127,259,131 after the offering, up from 118,851,954 as of June 30, 2025. The company highlights that investors will experience immediate dilution, estimating a $1.11 per-share dilution relative to adjusted net tangible book value. Management also notes its status as an emerging growth company and smaller reporting company, ongoing need for additional capital, and the historically volatile trading range of its Nasdaq-listed shares under the symbol TLSA.
Tiziana Life Sciences Ltd. is conducting a primary offering of common shares on a best efforts basis at $1.25 per share. For every common share purchased, investors receive one warrant to buy an additional common share at $1.50 at any time up to July 16, 2026.
The company estimates net proceeds of about $6.5 million, with no placement agent fees, to be used mainly to fund clinical development of its lead drug foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, plus working capital and general corporate purposes. Tiziana notes this financing will not be enough to complete its clinical programs and that further capital will be required.
As of June 30, 2025, the company had 118,851,954 common shares outstanding. The filing highlights risks including immediate dilution to new investors, potential share price volatility, and dependence on future financings to support ongoing trials and operations.
Tiziana Life Sciences Ltd. is conducting a primary best-efforts offering of common shares on Nasdaq to raise cash for its clinical-stage neurology pipeline. ThinkEquity LLC is acting as exclusive placement agent, but is not required to place any minimum number of shares, there is no minimum offering amount and no escrow account, so any funds received will be available to the company immediately.
The company plans to use net proceeds, together with existing cash, mainly to advance its lead candidate foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, and for working capital, capital spending and general corporate purposes. Because the offering price will be above the company’s net tangible book value, new investors are expected to incur immediate and substantial dilution, and future equity or debt financings could create additional dilution or restrictions. The prospectus also highlights volatility in TLSA’s share price and the likelihood that Tiziana will need further capital even after this offering.